Changes in ceramide concentrations and their association with clinical and anamnestic parameters in patients with acute coronary syndrome
E. I. Usova,
L. M. Malishevskii,
A. S. Alieva,
T. A. Makarova,
E. A. Murashko,
E. D. Kessenich,
S. N. Trusov,
M. S. Alieva,
A. N. Yakovlev,
A. O. Konradi https://doi.org/10.18705/2311-4495-2024-11-4-309-323
Abstract
Background. Given the metabolic dynamics of acute coronary syndrome (ACS), the study of molecular lipid metabolites is of particular importance because their composition most rapidly reflects the changes occurring at the time of the acute event. Several prospective studies have demonstrated the prognostic value of ceramides, however, the study of their dynamics and association with clinical parameters of patients with ACS is underrepresented. Objective. To investigate changes in Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0), and Cer(d18:1/24:1) ceramide concentrations and their association with clinical and anamnestic parameters in patients with ACS. Design and methods. Lipidomic analysis by high-performance liquid chromatography tandem mass spectrometry was performed among 110 patients with ACS. Results. At admission to the hospital the ceramide level was the highest and decreased with time (for all p < 0.001). The peculiarities of ceramide concentrations depending on clinical and anamnestic parameters of patients with ACS are shown. Ceramides were found to be weakly correlated with age and high-sensitivity troponin I, and moderately correlated with lipid profile at different time periods. For the first time, information on Cer(d18:1/16:0) and Cer(d18:1/24:0) levels depending on disease debut, Cer(d18:1/16:0) concentration depending on duration of the pain attack, and Cer(d18:1/18:0) level depending on the presence of family history of cardiovascular disease is presented. Conclusion. The dynamics of ceramide concentrations over time and the peculiarities of their levels depending on the clinical and anamnestic parameters of patients with ACS expand the understanding of the importance of lipid metabolites.
Keywords
acute coronary syndrome,
ceramides,
high-performance liquid chromatography tandem mass spectrometry,
lipidomic analysis
Supporting agencies: This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2022-301).
About the Authors
E. I. Usova
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Elena I. Usova, MD, postgraduate student of the Department of Cardiology, Faculty of Postgraduate and Additional Education, Institute of Medical Education, junior researcher, research laboratory of lipid disorders and atherosclerosis World-Class Research Centre for Personalized Medicine
Akkuratova str., 2, Saint Petersburg, 197341
Competing Interests:
The authors declare no conflict of interest
L. M. Malishevskii
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Lev M. Malishevskii, postgraduate student of the Department of Cardiovascular Surgery, Faculty of Postgraduate and Additional Education, Institute of Medical Education
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
A. S. Alieva
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Asiiat S. Alieva, MD, PhD, Head of laboratory of lipid disorders and atherosclerosis WCRC for Personalized Medicine, Head of the Center for Atherosclerosis and Lipid Disorders
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
T. A. Makarova
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Taiana A. Makarova, clinical pharmacologist, postgraduate student of the Department of Cardiology, Faculty of Postgraduate and Additional Education, Institute of Medical Education
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
E. A. Murashko
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina A. Murashko, PhD, head of Laboratory of metabolomic and metabolic profiling, Research Centre of unknown, rare and genetically determined diseases, WorldClass Research Centre for Personalized Medicine, assistant at the Department of Mathematics and Natural Sciences, Institute of Medical Education
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
E. D. Kessenich
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Elizaveta D. Kessenikh, scientific researcher of Laboratory of metabolomic and metabolic profiling, Research Centre of unknown, rare and genetically determined diseases, World-Class Research Centre for Personalized Medicine, postgraduate student of the Department of Cell Biology, Institute of Medical Education
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
S. N. Trusov
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Sergey N. Trusov, PhD, analytical chemist of Clinical diagnostic laboratory
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
M. S. Alieva
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Madina S. Alieva, anesthesiologist-intensive care specialist
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
A. N. Yakovlev
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Alexey N. Yakovlev, MD, PhD, Head of the Healthcare Development Service at the division of the Federal projects implementation, Head of the Research Laboratory for Cardiovascular Risk Prediction Technologies World-Class Research Centre for Personalized Medicine
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
A. O. Konradi
Almazov National Medical Research Centre
Russian Federation
Competing Interests:
Russian Federation
Alexandra O. Konradi, doctor of medical sciences, professor, RAS academician, Head of the Research Institute of Arterial Hypertension, Head of the Department of Organization of Management and Economics of Health Care, Institute of Medical Education, Deputy General Director for Research
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
References
1. Usova EI, Alieva AS, Yakovlev AN, et al. Integrative Analysis of Multi-Omics and Genetic Approaches-A New Level in Atherosclerotic Cardiovascular Risk Prediction. Biomolecules. 2021;11(11):1597. DOI: 10.3390/biom11111597.
2. McGurk KA, Keavney BD, Nicolaou A. Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies. Atherosclerosis. 2021;327:18–30. DOI: 10.1016/j.atherosclerosis.2021.04.021.
3. Cheng JM, Suoniemi M, Kardys I, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243(2):560–6. DOI: 10.1016/j.atherosclerosis.2015.10.022.
4. Meeusen JW, Donato LJ, Kopecky SL, et al. Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors. Clin Chim Acta. 2020;511:138–142. DOI: 10.1016/j.cca.2020.10.005.
5. Laaksonen R, Ekroos K, Sysi-Aho M, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967–76. DOI: 10.1093/eurheartj/ehw148.
6. Usova EI, Malishevskii LM, Alieva AS, et al. Analysis of predictors of recurrent acute cardiovascular events in patients with acute coronary syndrome. Russian Journal of Cardiology. 2024;29(6):5881. In Russian
7. Eggers LF, Schwudke D. Liquid Extraction: Folch. Encyclopedia of Lipidomics, 2016; 1–6. DOI:10.1007/978-94-007-7864-1_89-1.
8. Tan SH, Koh HWL, Chua JY, et al. Variability of the Plasma Lipidome and Subclinical Coronary Atherosclerosis. Arterioscler Thromb Vasc Biol. 2022;42(1):100–112. DOI: 10.1161/ATVBAHA.121.316847.
9. de Carvalho LP, Tan SH, Ow GS, et al. Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in Acute Myocardial Infarction. JACC Basic Transl Sci. 2018;3(2):163–175. DOI: 10.1016/j.jacbts.2017.12.005.
10. Burrello J, Biemmi V, Dei Cas M, et al. Sphingolipid composition of circulating extracellular vesicles after myocardial ischemia. Sci Rep. 2020;10(1):16182. DOI: 10.1038/s41598-020-73411-7.
11. Akhiyat N, Vasile V, Ahmad A, et al. Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction. J Am Heart Assoc. 2022;11(7):e022852. DOI: 10.1161/JAHA.121.022852.
12. Meeusen JW, Donato LJ, Bryant SC, et al. Plasma Ceramides. Arterioscler Thromb Vasc Biol. 2018;38(8):1933– 1939. DOI: 10.1161/ATVBAHA.118.311199.
13. Tu C, Xie L, Wang Z, et al. Association between ceramides and coronary artery stenosis in patients with coronary artery disease. Lipids Health Dis. 2020;19(1):151. DOI: 10.1186/s12944-020-01329-0.
14. Jensen PN, Fretts AM, Hoofnagle AN, et al. Plasma Ceramides and Sphingomyelins in Relation to Atrial Fibrillation Risk: The Cardiovascular Health Study. J Am Heart Assoc. 2020;9(4):e012853. DOI: 10.1161/JAHA.119.012853.
15. Gencer B, Morrow DA, Braunwald E, et al. Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Eur J Prev Cardiol. 2022;29(6):895–902. DOI: 10.1093/eurjpc/zwaa143.
16. Li F, Li D, Yu J, et al. Association Between Plasma Ceramides and One-Year Mortality in Patients with Acute Coronary Syndrome: Insight from the PEACP Study. Clin Interv Aging. 2023;18:571–584. DOI: 10.2147/CIA.S402253.
17. Gaggini M, Michelucci E, Ndreu R, et al. Lipidomic Analysis to Assess the Correlation between Ceramides, Stress Hyperglycemia, and HbA1c in Acute Myocardial Infarction. Molecules. 2023;28(2):716. DOI: 10.3390/molecules28020716.
18. Knapp M, Lisowska A, Knapp P, Baranowski M. Dose-dependent effect of aspirin on the level of sphingolipids in human blood. Adv Med Sci. 2013;58(2):274–81. DOI: 10.2478/ams-2013-0021.
19. Tarasov K, Ekroos K, Suoniemi M, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014;99(1):E45–52. DOI: 10.1210/jc.2013-2559.
20. Ng TW, Ooi EM, Watts GF, et al. Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome. J Clin Endocrinol Metab. 2014;99(11):e2335–40. DOI: 10.1210/jc.2014-1665.
21. Ye Q, Svatikova A, Meeusen JW, et al. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels. Am J Cardiol. 2020;128:163–167. DOI: 10.1016/j.amjcard.2020.04.052.
Review
For citations:
Usova E.I., Malishevskii L.M., Alieva A.S., Makarova T.A., Murashko E.A., Kessenich E.D., Trusov S.N., Alieva M.S., Yakovlev A.N., Konradi A.O. Changes in ceramide concentrations and their association with clinical and anamnestic parameters in patients with acute coronary syndrome. Translational Medicine. 2024;11(4):309-323. (In Russ.) https://doi.org/10.18705/2311-4495-2024-11-4-309-323
Views:
298
Email this article 